Comparison of these molecular findings using the IGCG/TCGA data showed that the differences between ITPN and conventional PDAC (for KRAS, TP53, CDKN2A, and SMAD4)/IPMN (for GNAS and RNF43) were significant. This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.